Plain-English translation of NCT03817502 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research trial is testing , a medication designed to treat schizophrenia, in teenagers between ages 13 and 17. The study will compare two different doses of the medication against a placebo (a pill with no active medicine) to see which works best and is safest. Researchers want to understand if this treatment can reduce schizophrenia symptoms like hallucinations and delusions in young people.
Most schizophrenia treatments have been tested mainly in adults, and doctors need better options specifically for teenagers. This trial aims to find out if the medication is both effective and safe for this younger age group, where schizophrenia can have a major impact on schooling and development.
You likely qualify if…
You likely don't qualify if…
You would take one capsule by mouth once a day for 6 weeks. You might receive either one of two doses of the medication or a placebo, decided randomly — neither you nor the study team will know which at first. You'll visit the clinic at least twice (at the start and end) for check-ins where doctors will ask about your symptoms and how you're feeling, and may do basic health tests to make sure the treatment is working safely.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States